This signature features known disease drivers and oncogenic ECM proteins associated with ovarian cancer progression and metastasis (e.g., NNMT, CD163, and FN1) (Eckert et al, 2019; Mitra et al, 2011; Lecker et al, 2021) and sheds light on proteins with high therapeutic potential. Here, FN1 is linked to ovarian carcinoma.